Lista de obras -

A Comparison of Testing Parameters and the Implementation of a Group Sequential Design for Equivalence Studies Using Paired-sample Analysis

artículo científico publicado en 2010

A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens

artículo científico publicado en 2011

A framework for assessing immunological correlates of protection in vaccine trials

artículo científico publicado en 2007

China and HIV Vaccine Research: An Old Country with a New Commitment

article

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

artículo científico publicado en 2005

Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials

artículo científico publicado en 2008

Endpoints in vaccine trials

scientific article published on 01 April 2004

Equivalence of ELISpot assays demonstrated between major HIV network laboratories

artículo científico publicado en 2010

Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection

artículo científico publicado en 2010

Evaluating a surrogate endpoint at three levels, with application to vaccine development

artículo científico publicado en 2008

Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys

artículo científico publicado en 2011

Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa

artículo científico publicado en 2008

HIV fragment gag vaccine induces broader T cell response in mice ⬇️

artículo científico publicado el 21 de marzo de 2011

HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.

artículo científico publicado en 2013

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

artículo científico publicado en 2008

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci

artículo científico publicado en 2017

How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?

artículo científico publicado en 2005

Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections

artículo científico publicado en 2009

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

artículo científico publicado en 2008

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study

artículo científico publicado en 2011

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

artículo científico publicado en 2018

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial

article by M Rolland et al published 22 October 2009 in Retrovirology

On estimating HLA/disease association with application to a study of aplastic anemia

scientific article published on 01 March 1991

On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials

artículo científico publicado en 2006

On testing departure from the binomial and multinomial assumptions.

artículo científico publicado en 1989

On the analysis of viral load endpoints in HIV vaccine trials

artículo científico publicado en 2003

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation

artículo científico publicado en 2006

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

artículo científico publicado en 2016

Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments

artículo científico publicado en 2009

Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost

article

Proceedings of the Frontiers of Retrovirology Conference 2016.

artículo científico publicado en 2016

Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys

artículo científico publicado en 2009

Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.

artículo científico publicado en 2009

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

artículo científico publicado en 2010

Statistical approaches to analyzing HIV-1 neutralizing antibody assay data

artículo científico publicado en 2012

Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials

artículo científico publicado en 2004

Statistical evaluation of HIV vaccines in early clinical trials.

artículo científico publicado en 2006

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials

artículo científico publicado en 2006

The Cox proportional hazards model with change point: an epidemiologic application

artículo científico publicado en 1990

The use of nonhuman primate models in HIV vaccine development

artículo científico publicado en 2008

Towards prediction of degenerate CTL epitope recognition

artículo científico publicado en 2008

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083

artículo científico publicado en 2015

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials

artículo científico publicado en 2003

Lista de obras de

A Comparison of Testing Parameters and the Implementation of a Group Sequential Design for Equivalence Studies Using Paired-sample Analysis

A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens

A framework for assessing immunological correlates of protection in vaccine trials

China and HIV Vaccine Research: An Old Country with a New Commitment

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials

Endpoints in vaccine trials

Equivalence of ELISpot assays demonstrated between major HIV network laboratories

Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection

Evaluating a surrogate endpoint at three levels, with application to vaccine development

Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys

Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa

HIV fragment gag vaccine induces broader T cell response in mice ⬇️

HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci

How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?

Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial

On estimating HLA/disease association with application to a study of aplastic anemia

On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials

On testing departure from the binomial and multinomial assumptions.

On the analysis of viral load endpoints in HIV vaccine trials

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments

Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost

Proceedings of the Frontiers of Retrovirology Conference 2016.

Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys

Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

Statistical approaches to analyzing HIV-1 neutralizing antibody assay data

Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials

Statistical evaluation of HIV vaccines in early clinical trials.

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials

The Cox proportional hazards model with change point: an epidemiologic application

The use of nonhuman primate models in HIV vaccine development

Towards prediction of degenerate CTL epitope recognition

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials